Department of TCM, The Affiliated Hospital of Qingdao University, Qingdao, China.
College of Basic TCM, Shandong University of Traditional Chinese Medicine, Jinan, China.
J Ethnopharmacol. 2021 May 23;272:113927. doi: 10.1016/j.jep.2021.113927. Epub 2021 Feb 16.
Shenling Baizhu San (SBS) as a classic Chinese medicine prescription, has been extensively used in gastrointestinal diseases, such as ulcerative colitis and chronic diarrhea. In recent years, SBS has shown a beneficial effect on chronic obstructive pulmonary disease (COPD) patients. However, clinical trials had shown conflicting results of SBS on improving pulmonary function and other related indicators of patients with stable COPD. The efficacy of SBS on stable COPD patients has not been fully assessed.
To determine whether the SBS used in the treatment of gastrointestinal disease was effective to treat COPD, we assessed the clinical evidence and efficacy of SBS supplemental treatment on stable COPD patients by a systematic review and meta-analysis of clinical trials.
Nine electronic databases were searched to include clinical trials (published until August 31, 2020) with SBS as a supplementation treatment on stable COPD. Mean difference (MD) was used to evaluate continuous variables, odds ratio (OR) was calculated to evaluate dichotomous. The Egger's test was applied for publication bias.
A total of 770 COPD participants from 11 trials that met the inclusion criteria were included. The meta-analysis showed that modified SBS could improve the exercise endurance, life quality scores of stable COPD patients, and also showed the potential benefits to pulmonary function of COPD patients than original SBS.
The methodological quality of included trials may limit the conclusions that indicate that modified SBS may have a promising treatment for improving FEV/FVC and MVV, increasing exercise endurance and life quality scores on stable COPD patients.
参灵白术散（SBS）作为一种经典的中药方剂，已广泛用于胃肠道疾病，如溃疡性结肠炎和慢性腹泻。近年来，SBS 对慢性阻塞性肺疾病（COPD）患者显示出有益的效果。然而，临床试验表明 SBS 对改善 COPD 患者的肺功能和其他相关指标的效果存在矛盾。SBS 对稳定期 COPD 患者的疗效尚未得到充分评估。
为了确定用于治疗胃肠道疾病的 SBS 是否对 COPD 有效，我们通过对临床试验的系统评价和荟萃分析，评估了 SBS 补充治疗稳定期 COPD 患者的临床证据和疗效。
检索了 9 个电子数据库，纳入了截止 2020 年 8 月 31 日以 SBS 作为补充治疗稳定期 COPD 的临床试验。采用均数差（MD）评估连续变量，采用比值比（OR）评估二分类变量。应用 Egger 检验评估发表偏倚。
共有 11 项符合纳入标准的试验，共纳入了 770 名 COPD 患者。荟萃分析显示，改良 SBS 可改善稳定期 COPD 患者的运动耐力、生活质量评分，也显示出对 COPD 患者的肺功能有潜在益处。
纳入试验的方法学质量可能限制了结论的得出，表明改良 SBS 可能对改善 FEV/FVC 和 MVV、提高运动耐力和稳定期 COPD 患者的生活质量评分具有一定的治疗前景。
